ESR1 and breast carcinoma: Treatment with buparlisib (PI3Kα/β/δ/γ inhibitor) reduced the expression of Wnt target genes AXIN2, LEF1, and MYCN in human PIK3CA-mutant ER+ breast cancer cells [25].